Jun 30, 2020

U.S. government contributed research to a Gilead remdesivir patent — but didn’t get credit

Posted by in categories: biotech/medical, government, health

Two documents dating back to 2015 shed further light on the role the federal government played in discovering remdesivir and its use in treating coronaviruses — work that has taken on new meaning as the Gilead Sciences (GILD) drug has gained global attention and an emergency use authorization from federal regulators to treat patients with Covid-19.

Reporting from the frontiers of health and medicine.

Comments are closed.